This was originally published on the Huffington Post on October 30, 2017.
Communicable diseases like HIV/AIDS and malaria have taken a
terrible toll on Kenya and other African countries over the last 20 years. In
2010, an
estimated 51,000 Kenyans died from AIDS but that number has declined
steadily, to 36,000 in 2016. Kenya is now considered an
HIV success story. The same is true in many other countries.
Now there is a new epidemic of non-communicable diseases (NCDs)
that is rising just as the world is starting to get a handle on communicable
diseases, according to the Institute for Health Metrics and Evaluation. The
Institute reports that the largest contributors to the loss of healthy life
are now high blood pressure, smoking, high blood sugar and excess
body weight.
But Dr.
Samuel Mwenda, who knows a thing or two about both epidemics, believes
there are lessons we have learned in the fight against communicable diseases
that can now be applied to NCDs. Mwenda is general secretary and CEO of the
Christian Health Association of Kenya (CHAK), a network of Protestant health
facilities in Kenya. CHAK now supports 46,000 people living with HIV with
antiretroviral therapy, representing about 9 percent of the total number of patients
nationally.
In 2015, CHAK turned its attention to NCDs: With the support
of Novartis
Access, it began offering a portfolio of 15 products to treat
cardiovascular disease, diabetes, respiratory illness and breast cancer at a
price to governments, NGOs and other institutional customers not to exceed
$1.00 per treatment per month. Since then, Novartis Access has also started working
in Cameroon, Ethiopia, Pakistan, Rwanda and Uganda.
Here are ten of the lessons Mwenda says CHAK and other
organizations have learned from communicable disease can also be applied to NCDs:
- Create partnerships: Partnerships are key. CHAK works with national and local governments, plus the private sector, academia, professional bodies and supply chain organizations.
- Mobilize and increase awareness: We must highlight lifestyle issues such as exposure to smoking and poor diet just like we did with HIV, TB and malaria. Once people are aware, provide screening to identify those with high blood pressure and abnormal blood sugars.
- Refer patients: Once you have flagged people, they must be linked with health facilities where they can get further assessment, diagnosis and care and treatment plans.
- Make treatment available: It’s imperative to have a reliable source of treatment. People will come to the facilities when they know they will get good quality medication. Novartis plays the key role in ensuring there are no stock-outs.
- Foster psycho-social support: In diabetes, CHAK started working with the Kenya Defeat Diabetes Association to mobilize people living with diabetes, helping them form groups for education, encouragement and advocacy.
- Work with faith groups and communities: In rolling out screening, CHAK links health facilities with churches and communities. This has helped CHAK reach many people at very little cost.
- Understand it’s a lifelong commitment: We need to commit to taking care of people their entire lives to ensure retention. As in HIV, this requires a lot of hard work in terms of following up to ensure that people come back for treatment.
- Train health providers: Lower level health cadres like nurses and clinical officers must be trained so they are able to handle diagnosis and treatment of NCDs.
- Emphasize integration: It’s important to integrate because those with communicable diseases are vulnerable to NCDs and we have begun to screen for hypertension and cervical cancer in HIV programs.
- Prioritize data: It’s very important to maintain data so we can track the magnitude of the burden and also inform policy and advocate for allocation of resources.
Similarly, Novartis’s work in malaria prompted the company
to go into NCDs. “Our work in malaria gave us the experience where we could
build on the lessons learned,” says Dr. Nathan Mulure, cluster head for
Novartis Social Business for East and Southern Africa. “We brought out a
product that was only reaching 100,000 treatments per year and increased that
to 100 million treatments. We figured that kind of scaling gave us the
experience we needed to try the same thing with NCDs.”
"At ministries of
health, I am often asked ‘Why are you doing this? What’s in it for Novartis?
Are you sure you’re not hiding anything?’ and I always tell them ‘There is
nothing hidden. This is a social business model, with low profit, but high
turnover, which will help the program to sustain itself over the long term. We
hope that if it catches fire, then many more patients will be able to access
high quality medicines at prices they can afford."
This article was
developed from a session at the 2017 Conference of Christian
Connections for International Health
on “Lessons from HIV and Malaria for Faith-Based Organizations in Africa’s
Transition to Managing NCDs.”
No comments:
Post a Comment